Cover Image

Probability of Target Attainment of Tobramycin Treatment in Acute and Chronic <i>Pseudomonas aeruginosa</i> Lung Infection Based on Preclinical Population Pharmacokinetic Modeling

Biofilms and infectious process may alter free antimicrobial concentrations at the site of infection. Tobramycin (TOB), an aminoglycoside used to treat lung infections caused by <i>Pseudomonas aeruginosa</i>, binds to alginate present in biofilm extracellular matrix increasing its minimu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bruna Bernar Dias (Author), Fernando Carreño (Author), Victória Etges Helfer (Author), Priscila Martini Bernardi Garzella (Author), Daiane Maria Fonseca de Lima (Author), Fabiano Barreto (Author), Bibiana Verlindo de Araújo (Author), Teresa Dalla Costa (Author)
Format:	Book
Published:	MDPI AG, 2022-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exploring Antibiotic-Potentiating Effects of Tobramycin-Deferiprone Conjugates in <i>Pseudomonas aeruginosa</i>
by: Karan Gandhi, et al.
Published: (2023)

Itaconic Acid Increases the Efficacy of Tobramycin against <i>Pseudomonas aeruginosa</i> Biofilms
by: Duy-Khiet Ho, et al.
Published: (2020)

Role of Tobramycin in the Induction and Maintenance of Viable but Non-Culturable <i>Pseudomonas aeruginosa</i> in an In Vitro Biofilm Model
by: Gianmarco Mangiaterra, et al.
Published: (2020)

Evaluation of Tobramycin and Ciprofloxacin as a Synergistic Combination Against Hypermutable <i>Pseudomonas Aeruginosa</i> Strains via Mechanism-Based Modelling
by: Vanessa E. Rees, et al.
Published: (2019)

Liposome-Encapsulated Tobramycin and IDR-1018 Peptide Mediated Biofilm Disruption and Enhanced Antimicrobial Activity against <i>Pseudomonas aeruginosa</i>
by: Nouf M. Alzahrani, et al.
Published: (2022)

Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected <i>Pseudomonas aeruginosa</i> Infection
by: Annabel Werumeus Buning, et al.
Published: (2021)

Ceftazidime/Tobramycin Co-Loaded Chitosan-Coated Zein Nanoparticles against Antibiotic-Resistant and Biofilm-Producing <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i>
by: Luís André de Almeida Campos, et al.
Published: (2024)

A Cationic Porphyrin, ZnPor, Disassembles <i>Pseudomonas aeruginosa</i> Biofilm Matrix, Kills Cells Directly, and Enhances Antibiotic Activity of Tobramycin
by: Neha Patel, et al.
Published: (2020)

Antimicrobial Synergy Testing: Comparing the Tobramycin and Ceftazidime Gradient Diffusion Methodology Used in Assessing Synergy in Cystic Fibrosis-Derived Multidrug-Resistant <i>Pseudomonas aeruginosa</i>
by: Ijeoma N. Okoliegbe, et al.
Published: (2021)

Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
by: Jessica R. Tait, et al.
Published: (2022)

<i>Pseudomonas aeruginosa</i> Biofilm Formation, Infections and Treatments
Published: (2021)

Treatment Heterogeneity in <i>Pseudomonas aeruginosa</i> Pneumonia
by: Aisling R. Caffrey, et al.
Published: (2022)

Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
by: Yuta Ibe, et al.
Published: (2023)

Antimicrobial Treatment of <i>Pseudomonas aeruginosa</i> Severe Sepsis
by: Johnny Zakhour, et al.
Published: (2022)

The Basis for Natural Multiresistance to Phage in <i>Pseudomonas aeruginosa</i>
by: Christine Pourcel, et al.
Published: (2020)

Spiramycin Disarms <i>Pseudomonas aeruginosa</i> without Inhibiting Growth
by: Matteo Calcagnile, et al.
Published: (2023)

Bacteriophage-Antibiotic Combination Therapy against <i>Pseudomonas aeruginosa</i>
by: Guillermo Santamaría-Corral, et al.
Published: (2023)

Sub-Inhibitory Antibiotic Exposure and Virulence in <i>Pseudomonas aeruginosa</i>
by: Charlotte Nolan, et al.
Published: (2021)

Detection of extended-spectrum β-lactamase in <i>Pseudomonas aeruginosa</i>
by: Aggarwal Ritu, et al.
Published: (2008)

Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and <i>N</i>-Acetylcysteine against Tobramycin-Resistant <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Acinetobacter baumannii</i>
by: Reem E. Alarfaj, et al.
Published: (2022)

Trends in <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>) Bacteremia during the COVID-19 Pandemic: A Systematic Review
by: Qin Xiang Ng, et al.
Published: (2023)

Antimicrobial susceptibility of <i>Pseudomonas aeruginosa</i> isolated from wound infections
by: Anupurba Shampa, et al.
Published: (2006)

Exposure of <i>Pseudomonas aeruginosa</i> to Cinnamaldehyde Selects Multidrug Resistant Mutants
by: Alexandre Tetard, et al.
Published: (2022)

Intravenous Fosfomycin for Systemic Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections
by: Giuseppe Pipitone, et al.
Published: (2023)

Characteristics of Antibiotic Resistance and Tolerance of Environmentally Endemic <i>Pseudomonas aeruginosa</i>
by: Seryoung Kim, et al.
Published: (2022)

Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by <i>Pseudomonas aeruginosa</i>
by: George L. Daikos, et al.
Published: (2021)

Thermal Shock and Ciprofloxacin Act Orthogonally on <i>Pseudomonas aeruginosa</i> Biofilms
by: Haydar Aljaafari, et al.
Published: (2021)

The In Vivo and In Vitro Assessment of Pyocins in Treating <i>Pseudomonas aeruginosa</i> Infections
by: Abdulaziz Alqahtani, et al.
Published: (2022)

XDR-<i>Pseudomonas aeruginosa</i> Outside the ICU: Is There Still Place for Colistin?
by: Paola Del Giacomo, et al.
Published: (2022)

Recent Advance in Small Molecules Targeting RhlR of <i>Pseudomonas</i> <i>aeruginosa</i>
by: Taehyeong Lim, et al.
Published: (2022)

Identification of Efflux Pump Mutations in <i>Pseudomonas aeruginosa</i> from Clinical Samples
by: Sonia Quddus, et al.
Published: (2023)

Indazole-Quinolone Hybrids as Anti-Virulence Agents against <i>Pseudomonas aeruginosa</i>
by: Marie Hanot, et al.
Published: (2024)

Unveiling the Anti-Biofilm Property of Hydroxyapatite on <i>Pseudomonas aeruginosa</i>: Synthesis and Strategy
by: Davoodbasha MubarakAli, et al.
Published: (2023)

Genetic Alternatives for Experimental Adaptation to Colistin in Three <i>Pseudomonas aeruginosa</i> Lineages
by: Igor Chebotar, et al.
Published: (2024)

A Study of Metabolites from Basidiomycota and Their Activities against <i>Pseudomonas aeruginosa</i>
by: Marco Clericuzio, et al.
Published: (2024)

Synergy between Indoloquinolines and Ciprofloxacin: An Antibiofilm Strategy against <i>Pseudomonas aeruginosa</i>
by: Emilie Charpentier, et al.
Published: (2021)

Dynamic Adaptive Response of <i>Pseudomonas aeruginosa</i> to Clindamycin/Rifampicin-Impregnated Catheters
by: Kidon Sung, et al.
Published: (2021)

Retrospective Data Insight into the Global Distribution of Carbapenemase-Producing <i>Pseudomonas aeruginosa</i>
by: Min-Ge Wang, et al.
Published: (2021)

Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment for <i>Pseudomonas aeruginosa</i> Infections
by: Erlinda R. Ulloa, et al.
Published: (2022)

Role of Relebactam in the Antibiotic Resistance Acquisition in <i>Pseudomonas aeruginosa</i>: In Vitro Study
by: Maria Paz Ventero, et al.
Published: (2023)